|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NABP2 |
Gene summary for NABP2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NABP2 | Gene ID | 79035 |
| Gene name | nucleic acid binding protein 2 | |
| Gene Alias | OBFC2B | |
| Cytomap | 12q13.3 | |
| Gene Type | protein-coding | GO ID | GO:0000075 | UniProtAcc | A0A024RB89 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79035 | NABP2 | LZE4T | Human | Esophagus | ESCC | 6.56e-05 | 1.95e-01 | 0.0811 |
| 79035 | NABP2 | LZE7T | Human | Esophagus | ESCC | 1.47e-08 | 6.33e-01 | 0.0667 |
| 79035 | NABP2 | LZE8T | Human | Esophagus | ESCC | 1.12e-10 | 2.81e-01 | 0.067 |
| 79035 | NABP2 | LZE22T | Human | Esophagus | ESCC | 2.29e-04 | 3.49e-01 | 0.068 |
| 79035 | NABP2 | LZE24T | Human | Esophagus | ESCC | 2.62e-19 | 5.53e-01 | 0.0596 |
| 79035 | NABP2 | LZE21T | Human | Esophagus | ESCC | 1.34e-04 | 3.42e-01 | 0.0655 |
| 79035 | NABP2 | LZE6T | Human | Esophagus | ESCC | 8.01e-07 | 4.76e-01 | 0.0845 |
| 79035 | NABP2 | P1T-E | Human | Esophagus | ESCC | 3.43e-06 | 4.60e-01 | 0.0875 |
| 79035 | NABP2 | P2T-E | Human | Esophagus | ESCC | 5.76e-38 | 8.18e-01 | 0.1177 |
| 79035 | NABP2 | P4T-E | Human | Esophagus | ESCC | 4.96e-31 | 7.67e-01 | 0.1323 |
| 79035 | NABP2 | P5T-E | Human | Esophagus | ESCC | 2.93e-31 | 6.76e-01 | 0.1327 |
| 79035 | NABP2 | P8T-E | Human | Esophagus | ESCC | 6.48e-26 | 5.59e-01 | 0.0889 |
| 79035 | NABP2 | P9T-E | Human | Esophagus | ESCC | 2.42e-17 | 3.75e-01 | 0.1131 |
| 79035 | NABP2 | P10T-E | Human | Esophagus | ESCC | 1.91e-28 | 5.58e-01 | 0.116 |
| 79035 | NABP2 | P11T-E | Human | Esophagus | ESCC | 3.19e-16 | 5.86e-01 | 0.1426 |
| 79035 | NABP2 | P12T-E | Human | Esophagus | ESCC | 2.50e-29 | 5.95e-01 | 0.1122 |
| 79035 | NABP2 | P15T-E | Human | Esophagus | ESCC | 9.17e-20 | 4.82e-01 | 0.1149 |
| 79035 | NABP2 | P16T-E | Human | Esophagus | ESCC | 9.24e-27 | 5.64e-01 | 0.1153 |
| 79035 | NABP2 | P17T-E | Human | Esophagus | ESCC | 2.16e-14 | 4.69e-01 | 0.1278 |
| 79035 | NABP2 | P19T-E | Human | Esophagus | ESCC | 8.33e-10 | 1.28e+00 | 0.1662 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0072594110 | Esophagus | ESCC | establishment of protein localization to organelle | 311/8552 | 422/18723 | 3.02e-32 | 2.13e-29 | 311 |
| GO:003304416 | Esophagus | ESCC | regulation of chromosome organization | 145/8552 | 187/18723 | 3.80e-19 | 4.31e-17 | 145 |
| GO:004477216 | Esophagus | ESCC | mitotic cell cycle phase transition | 281/8552 | 424/18723 | 4.63e-18 | 4.45e-16 | 281 |
| GO:000734615 | Esophagus | ESCC | regulation of mitotic cell cycle | 293/8552 | 457/18723 | 8.00e-16 | 5.64e-14 | 293 |
| GO:005105215 | Esophagus | ESCC | regulation of DNA metabolic process | 232/8552 | 359/18723 | 2.40e-13 | 1.13e-11 | 232 |
| GO:001021217 | Esophagus | ESCC | response to ionizing radiation | 110/8552 | 148/18723 | 1.11e-12 | 4.78e-11 | 110 |
| GO:000072319 | Esophagus | ESCC | telomere maintenance | 99/8552 | 131/18723 | 2.68e-12 | 1.08e-10 | 99 |
| GO:005105417 | Esophagus | ESCC | positive regulation of DNA metabolic process | 139/8552 | 201/18723 | 1.20e-11 | 4.33e-10 | 139 |
| GO:190198713 | Esophagus | ESCC | regulation of cell cycle phase transition | 242/8552 | 390/18723 | 3.86e-11 | 1.26e-09 | 242 |
| GO:000931419 | Esophagus | ESCC | response to radiation | 277/8552 | 456/18723 | 4.42e-11 | 1.43e-09 | 277 |
| GO:003220417 | Esophagus | ESCC | regulation of telomere maintenance | 65/8552 | 80/18723 | 6.02e-11 | 1.90e-09 | 65 |
| GO:190199013 | Esophagus | ESCC | regulation of mitotic cell cycle phase transition | 191/8552 | 299/18723 | 1.35e-10 | 3.94e-09 | 191 |
| GO:00457865 | Esophagus | ESCC | negative regulation of cell cycle | 236/8552 | 385/18723 | 3.62e-10 | 9.93e-09 | 236 |
| GO:00000754 | Esophagus | ESCC | cell cycle checkpoint | 117/8552 | 169/18723 | 4.47e-10 | 1.17e-08 | 117 |
| GO:200125219 | Esophagus | ESCC | positive regulation of chromosome organization | 64/8552 | 82/18723 | 1.98e-09 | 4.52e-08 | 64 |
| GO:003450211 | Esophagus | ESCC | protein localization to chromosome | 70/8552 | 92/18723 | 2.54e-09 | 5.64e-08 | 70 |
| GO:00448394 | Esophagus | ESCC | cell cycle G2/M phase transition | 103/8552 | 148/18723 | 3.09e-09 | 6.67e-08 | 103 |
| GO:00000864 | Esophagus | ESCC | G2/M transition of mitotic cell cycle | 96/8552 | 137/18723 | 6.00e-09 | 1.23e-07 | 96 |
| GO:00070934 | Esophagus | ESCC | mitotic cell cycle checkpoint | 90/8552 | 129/18723 | 2.49e-08 | 4.69e-07 | 90 |
| GO:003220618 | Esophagus | ESCC | positive regulation of telomere maintenance | 42/8552 | 52/18723 | 2.15e-07 | 3.30e-06 | 42 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NABP2 | SNV | Missense_Mutation | c.238N>T | p.Gly80Cys | p.G80C | Q9BQ15 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| NABP2 | deletion | Frame_Shift_Del | c.238delN | p.Gly80ValfsTer3 | p.G80Vfs*3 | Q9BQ15 | protein_coding | TCGA-A1-A0SK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |||
| NABP2 | SNV | Missense_Mutation | novel | c.613N>G | p.Thr205Ala | p.T205A | Q9BQ15 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.899) | TCGA-CK-5916-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| NABP2 | SNV | Missense_Mutation | c.194N>A | p.Gly65Glu | p.G65E | Q9BQ15 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| NABP2 | SNV | Missense_Mutation | rs151118817 | c.533N>A | p.Arg178Gln | p.R178Q | Q9BQ15 | protein_coding | tolerated(0.38) | possibly_damaging(0.885) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NABP2 | SNV | Missense_Mutation | novel | c.178N>G | p.Asn60Asp | p.N60D | Q9BQ15 | protein_coding | tolerated(0.29) | benign(0.03) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NABP2 | SNV | Missense_Mutation | novel | c.4N>G | p.Thr2Ala | p.T2A | Q9BQ15 | protein_coding | tolerated_low_confidence(0.18) | benign(0.11) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| NABP2 | SNV | Missense_Mutation | c.319N>G | p.Asn107Asp | p.N107D | Q9BQ15 | protein_coding | deleterious(0) | benign(0.241) | TCGA-CC-A7IH-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
| NABP2 | SNV | Missense_Mutation | c.320N>T | p.Asn107Ile | p.N107I | Q9BQ15 | protein_coding | deleterious(0) | probably_damaging(0.957) | TCGA-UB-A7MB-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Targeted Molecular therapy | sorafenib | PD | |
| NABP2 | SNV | Missense_Mutation | novel | c.37N>T | p.Gly13Trp | p.G13W | Q9BQ15 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-05-4396-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |